Juan Carlos Hernández-Boluda, MD, PhD, details the advantages of EBMT machine learning vs existing transplant risk assessment tools in myelofibrosis.
Juan Carlos Hernández-Boluda, MD, PhD
Advertisement
Juan Carlos Hernández-Boluda, MD, PhD, is an associated physician at the Hematology and Medical Oncology Service of the Hospital Clínico of Valencia
Articles by Juan Carlos Hernández-Boluda, MD, PhD
Juan Carlos Hernández-Boluda, MD, PhD, discusses the rationale for using machine learning to predict OS outcomes after allo-HCT in myelofibrosis.
Juan Carlos Hernández-Boluda, MD, PhD, discusses an EBMT machine learning–based model for identifying and stratifying transplant risk in myelofibrosis.
Advertisement
Latest Updated Articles
Dr Hernández-Boluda on an EBMT Machine Learning Model for Identifying and Stratifying Transplant Risk in MyelofibrosisPublished: March 31st 2025 | Updated:
Dr Hernández-Boluda on Machine Learning for Identifying Transplant Risk in MyelofibrosisPublished: May 5th 2025 | Updated:
- Dr Hernández-Boluda on the Rationale for Using Machine Learning to Predict Post-HCT Outcomes in Myelofibrosis
Published: April 14th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5